CRL Charles River Laboratories International, Inc.
$292.84
Charles River Laboratories International, Inc. (CRL) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is $2.96 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +9.3% since its last earnings release on August 5, 2026.
Charles River Laboratories International Beat Consensus Estimates, Raises Guidance
Wednesday, August 5, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 7:00 AM ET
Earnings Whisper
-
vs $2.96
Rev est $955.44M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP
$281.69
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Charles River Laboratories International, Inc.
Charles River Laboratories International Inc provides research models and services required to enable in vivo drug discovery and development.
Sector
Healthcare
Industry
Research Services
Held By 10 ETFs, by dollar flow
- IYH iShares U.S. Healthcare ETF
- IYH iShares U.S. Healthcare ETF
- XLV Health Care Select Sector SPDR Fund
- XLV Health Care Select Sector SPDR Fund
- IXJ iShares Global Healthcare ETF
- IXJ iShares Global Healthcare ETF
- BMED iShares Health Innovation Active ETF
- BMED iShares Health Innovation Active ETF
- BBH VanEck Biotech ETF
- BBH VanEck Biotech ETF
Charts powered in part by Lightweight Charts™ by TradingView.